Sector: HealthcareIndustry: Drug Manufacturers - GeneralCIK:0000059478
Market Cap900.54 Bn
P/E35.71
P/S12.46
Div. Yield0.01
ROIC (Qtr)0.00
Total Debt (Qtr)43.37 Bn
Revenue Growth (1y) (Qtr)55.54
Add ratio to table...
About
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products. The company aims to unite caring with discovery to create medicines that improve life for people worldwide. It operates in approximately 90 countries and maintains manufacturing sites in the United States, Europe and Asia. Eli Lilly and Company focuses its research and development efforts on cardiometabolic health, oncology, immunology and neuroscience to address unmet medical needs. The company’s portfolio includes insulin analogs, glucagon like...
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products. The company aims to unite caring with discovery to create medicines that improve life for people worldwide. It operates in approximately 90 countries and maintains manufacturing sites in the United States, Europe and Asia. Eli Lilly and Company focuses its research and development efforts on cardiometabolic health, oncology, immunology and neuroscience to address unmet medical needs. The company’s portfolio includes insulin analogs, glucagon like peptide 1 receptor agonists, anticancer agents, immunomodulators and neuroscience therapeutics. Its products are distributed through a network that reaches hospitals, clinics and retail outlets in nearly all major markets.
Revenue is generated primarily from the sale of its pharmaceutical products to wholesalers, pharmacy benefit managers, insurers, plan sponsors, employers, managed care organizations, group purchasing organizations, government and long term care institutions, hospitals and retail pharmacies. In the United States, 3 wholesale distributors, McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc., each accounted for a significant portion of consolidated revenue in 2023, 2024 and 2025. The company also earns revenue through collaborations and licensing agreements with other biotechnology and pharmaceutical firms that collaborate to develop and market certain products. The company’s collaborations with Boehringer Ingelheim for Jardiance and with Incyte for Olumiant generate milestone payments, royalties and profit sharing. LillyDirect, a direct to patient platform, enables select medicines to be shipped from third party pharmacies to patients while offering adherence support tools and disease education resources. International sales are supported by local sales forces and third party distributors that adapt marketing and distribution to meet regional regulatory requirements.
The company operates through the following segments:
• Human pharmaceutical products: This segment discovers, develops, manufactures, and markets medicines across therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience.
Eli Lilly and Company ranks among the largest global pharmaceutical companies, competing with firms such as Pfizer, Merck, Novo Nordisk, and Roche. Its competitive advantages stem from a deep pipeline of innovative medicines, strong intellectual property protection, extensive global manufacturing footprint, and strategic collaborations with other biotechnology firms. The company’s ability to bring differentiated products to market quickly helps it maintain relevance in highly therapeutic areas where effectiveness, safety, and payer coverage are critical. Lilly’s sustained investment in research and development, which employed approximately 12,000 scientists and technical staff at the end of 2025, fuels a steady flow of new drug candidates and line extensions. The firm’s scale enables it to negotiate favorable terms with suppliers and payers while maintaining a diversified geographic revenue base that reduces reliance on any single market. The company’s pipeline includes candidates such as insulin efsitora alfa and orforglipron, which are under regulatory review for diabetes and obesity. Continuous investment in manufacturing capacity has expanded production sites in the United States, Europe and Asia to meet growing demand.
The company serves a diverse customer base that includes major wholesale distributors such as McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.; numerous pharmacy benefit managers; insurers; hospitals; physicians; and patients. Through its LillyDirect platform, Eli Lilly and Company also reaches individual consumers seeking home delivery of prescribed medicines. Long term care facilities, managed care organizations and government agencies constitute important purchasers for therapies addressing chronic conditions such as diabetes and cancer. Physician offices and academic medical centers serve as key prescribers who influence product adoption through clinical guidelines and formulary recommendations. Retail pharmacies and chain drug stores provide final dispensing points that connect Lilly’s medicines with everyday consumers. No single customer other than the 3 major wholesalers accounted for more than 10% of consolidated revenue in recent years.
Eli Lilly’s latest earnings demonstrate a rare convergence of revenue growth, margin stability, and market‑share expansion, all of which point to a robust growth trajectory that the market has yet to fully price in. The company posted a 45% rise in full‑year revenue, largely driven by the explosive volume gains of Mounjaro and Zepbound, and an 86% increase in EPS, underscoring an efficient capital‑allocation strategy that boosts shareholder value while still investing heavily in R&D. Even as realized US prices fell 7% year‑over‑year, the company’s ability to offset that loss through volume growth in both diabetes and obesity markets signals a resilient pricing power that can sustain the 25% top‑line lift outlined in its 2026 guidance. This volume‑driven momentum is especially compelling given the company’s high market‑share targets—over 55% in new type‑two diabetes prescriptions and 70% in new branded obesity prescriptions—hinting at a durable advantage in these fast‑growing therapeutic areas.
The upcoming Medicare coverage for obesity therapies, slated to take effect no later than July 1, 2026, is a hidden catalyst that can open a 40 million‑patient pool to Lilly’s high‑efficacy drugs while keeping out‑of‑pocket costs low at $50. By leveraging its direct‑to‑patient platform, which already engaged one million US patients, Lilly is positioned to capture early adopters and create brand loyalty in a consumer‑driven market segment that is increasingly moving away from insurer‑dependent models. The company’s strategic pricing of Zepbound self‑pay vials, which now comprise nearly one‑third of all new obesity starts, further demonstrates its ability to tailor product offerings to consumer price sensitivities, thereby unlocking volume that traditional payer models may miss. With Medicare’s expansion, Lilly can now deliver its proven GLP‑1s to a broader demographic, ensuring that the 2026 revenue outlook remains realistic even under the anticipated price drag.
Lilly’s R&D engine has entered a phase of unprecedented breadth, featuring 36 active Phase III programs, 14 newly initiated studies, and breakthrough therapy designation for sofetibart. The company’s pipeline now spans cardiometabolic, oncology, immunology, and neuroscience, reducing dependence on any single therapeutic area. In addition to conventional discovery, Lilly has entered an AI‑powered co‑innovation lab with NVIDIA, a partnership that promises to accelerate early‑stage candidate identification and de‑risk clinical development timelines. The recently announced collaboration with Scribe Therapeutics, which has reached a second success milestone in CRISPR‑based gene editing, adds a potential high‑margin, transformative product line that could diversify Lilly’s revenue sources beyond prescription drugs. This diversified pipeline not only spreads risk but also creates a series of future blockbuster candidates that can sustain the company’s growth trajectory in the post‑inflationary era.
A cornerstone of Lilly’s supply‑chain resilience is its aggressive manufacturing expansion, having invested over $55 billion since 2020 and opened new facilities in Wisconsin and North Carolina. The company now produces 1.8 times the number of incretin doses it did in 2024, a capacity that comfortably supports its rapid volume growth in Mounjaro and Zepbound. The decision to build a manufacturing hub in India further strengthens Lilly’s global supply footprint, allowing it to tap a robust contract‑manufacturing ecosystem and reduce logistics bottlenecks, especially for its emerging weight‑loss portfolio. This infrastructure underpins the company’s ability to meet demand spikes, maintain product availability, and potentially reduce unit production costs—factors that can be passed on to customers and help sustain pricing flexibility.
Lilly’s financial discipline, evidenced by an 83.2% gross margin and a 47.2% non‑GAAP performance margin, provides a robust cushion for the company to continue rewarding shareholders. The firm paid $1.3 billion in dividends and repurchased $1.5 billion of shares in 2025, signaling confidence in its cash‑flow generation while also signaling a commitment to returning value to shareholders. Coupled with a strong balance sheet, this financial flexibility allows Lilly to invest aggressively in its pipeline and marketing without jeopardizing liquidity. Moreover, the company’s ability to maintain high margins even as it increases R&D and marketing spend demonstrates effective cost control, which is vital in an industry increasingly beset by pricing headwinds.
Eli Lilly’s latest earnings demonstrate a rare convergence of revenue growth, margin stability, and market‑share expansion, all of which point to a robust growth trajectory that the market has yet to fully price in. The company posted a 45% rise in full‑year revenue, largely driven by the explosive volume gains of Mounjaro and Zepbound, and an 86% increase in EPS, underscoring an efficient capital‑allocation strategy that boosts shareholder value while still investing heavily in R&D. Even as realized US prices fell 7% year‑over‑year, the company’s ability to offset that loss through volume growth in both diabetes and obesity markets signals a resilient pricing power that can sustain the 25% top‑line lift outlined in its 2026 guidance. This volume‑driven momentum is especially compelling given the company’s high market‑share targets—over 55% in new type‑two diabetes prescriptions and 70% in new branded obesity prescriptions—hinting at a durable advantage in these fast‑growing therapeutic areas.
The upcoming Medicare coverage for obesity therapies, slated to take effect no later than July 1, 2026, is a hidden catalyst that can open a 40 million‑patient pool to Lilly’s high‑efficacy drugs while keeping out‑of‑pocket costs low at $50. By leveraging its direct‑to‑patient platform, which already engaged one million US patients, Lilly is positioned to capture early adopters and create brand loyalty in a consumer‑driven market segment that is increasingly moving away from insurer‑dependent models. The company’s strategic pricing of Zepbound self‑pay vials, which now comprise nearly one‑third of all new obesity starts, further demonstrates its ability to tailor product offerings to consumer price sensitivities, thereby unlocking volume that traditional payer models may miss. With Medicare’s expansion, Lilly can now deliver its proven GLP‑1s to a broader demographic, ensuring that the 2026 revenue outlook remains realistic even under the anticipated price drag.
Lilly’s R&D engine has entered a phase of unprecedented breadth, featuring 36 active Phase III programs, 14 newly initiated studies, and breakthrough therapy designation for sofetibart. The company’s pipeline now spans cardiometabolic, oncology, immunology, and neuroscience, reducing dependence on any single therapeutic area. In addition to conventional discovery, Lilly has entered an AI‑powered co‑innovation lab with NVIDIA, a partnership that promises to accelerate early‑stage candidate identification and de‑risk clinical development timelines. The recently announced collaboration with Scribe Therapeutics, which has reached a second success milestone in CRISPR‑based gene editing, adds a potential high‑margin, transformative product line that could diversify Lilly’s revenue sources beyond prescription drugs. This diversified pipeline not only spreads risk but also creates a series of future blockbuster candidates that can sustain the company’s growth trajectory in the post‑inflationary era.
A cornerstone of Lilly’s supply‑chain resilience is its aggressive manufacturing expansion, having invested over $55 billion since 2020 and opened new facilities in Wisconsin and North Carolina. The company now produces 1.8 times the number of incretin doses it did in 2024, a capacity that comfortably supports its rapid volume growth in Mounjaro and Zepbound. The decision to build a manufacturing hub in India further strengthens Lilly’s global supply footprint, allowing it to tap a robust contract‑manufacturing ecosystem and reduce logistics bottlenecks, especially for its emerging weight‑loss portfolio. This infrastructure underpins the company’s ability to meet demand spikes, maintain product availability, and potentially reduce unit production costs—factors that can be passed on to customers and help sustain pricing flexibility.
Lilly’s financial discipline, evidenced by an 83.2% gross margin and a 47.2% non‑GAAP performance margin, provides a robust cushion for the company to continue rewarding shareholders. The firm paid $1.3 billion in dividends and repurchased $1.5 billion of shares in 2025, signaling confidence in its cash‑flow generation while also signaling a commitment to returning value to shareholders. Coupled with a strong balance sheet, this financial flexibility allows Lilly to invest aggressively in its pipeline and marketing without jeopardizing liquidity. Moreover, the company’s ability to maintain high margins even as it increases R&D and marketing spend demonstrates effective cost control, which is vital in an industry increasingly beset by pricing headwinds.
Despite impressive growth, Lilly faces a series of mounting pricing headwinds that could materially compress revenue and margin in 2026 and beyond. The company disclosed a 7% decline in average US price for key products, a trend that is projected to continue in the low‑to‑mid‑teens percentage range due to Medicare and Medicaid agreements and direct‑to‑consumer price reductions. The most immediate threat is the mandated price concessions under the Trump‑era “most‑favored‑nation” agreement, which will force Lilly to lower its retail price for obesity therapies in the Medicare population, potentially eroding the higher revenue gains seen in 2025. Furthermore, anticipated Medicaid coverage reductions in key states such as California may reduce overall payer reach for Lilly’s later‑life‑cycle products, compounding the pressure on the company’s earnings.
Lilly’s dominance in the GLP‑1 obesity market is increasingly vulnerable to competitive pressures, both from established rivals and new entrants. Novo Nordisk’s Wegovy pill, already launched in the United States, offers a once‑daily oral formulation that has been rapidly adopted by patients seeking convenience, creating a direct substitute that could erode Lilly’s market share. In addition, the market is now subject to a wave of generic and “compounded” versions, exemplified by Hims & Hers’ low‑price oral copy, which threaten to dilute the perceived value of Lilly’s branded products. The company’s own recent data on Retatrutide also highlights higher discontinuation rates in lower‑BMI patients, raising concerns about long‑term adherence and safety that could dampen adoption.
While Lilly’s existing drugs enjoy robust patent protection until the late 2030s, the company is not immune to the broader industry’s patent‑cliff reality. Products such as Verzenio have already plateaued, and late‑life‑cycle medicines like Trulicity and Talsa are expected to be flat or decline, underscoring the cyclical nature of blockbuster revenue. Additionally, the company’s reliance on a few high‑margin assets makes it vulnerable to unexpected regulatory changes or safety concerns that could accelerate patent expiry or force product withdrawals. The potential influx of biosimilar and generic competition in China and other markets could further compress margins, especially for drugs that have yet to secure robust global reimbursement frameworks.
The breadth of Lilly’s pipeline, while a source of upside, also introduces significant regulatory and execution risk. Orforglipron, Lilly’s first oral weight‑loss drug, is still pending FDA approval, and its commercial launch timing remains uncertain, which could delay the expected volume expansion. Retatrutide’s Phase III data, although promising, revealed discontinuation rates tied to perceived excessive weight loss, a red flag that could impede regulatory acceptance or post‑market adoption. Moreover, the company’s aggressive acquisition strategy—spending billions on assets such as Scribe Therapeutics, Orna Therapeutics, and Innovent Biologics—may dilute management focus and increase integration complexity, potentially hampering the execution of its core pipeline priorities.
Finally, macro‑economic and policy uncertainties loom over Lilly’s growth prospects. Rising inflation and higher interest rates could suppress consumer discretionary spending, directly impacting the direct‑to‑consumer model that Lilly is heavily investing in. Unpredictable policy shifts, especially at the state level regarding Medicaid coverage and reimbursement rates, could alter the payer mix in unforeseen ways. The broader pharmaceutical environment is also experiencing heightened scrutiny over drug pricing and value‑based reimbursement, which may result in tighter pricing controls or accelerated reimbursement denial for newer therapies. Together, these factors could erode both volume and margin, making Lilly’s 2026 guidance an optimistic target amid a highly uncertain landscape.
Despite impressive growth, Lilly faces a series of mounting pricing headwinds that could materially compress revenue and margin in 2026 and beyond. The company disclosed a 7% decline in average US price for key products, a trend that is projected to continue in the low‑to‑mid‑teens percentage range due to Medicare and Medicaid agreements and direct‑to‑consumer price reductions. The most immediate threat is the mandated price concessions under the Trump‑era “most‑favored‑nation” agreement, which will force Lilly to lower its retail price for obesity therapies in the Medicare population, potentially eroding the higher revenue gains seen in 2025. Furthermore, anticipated Medicaid coverage reductions in key states such as California may reduce overall payer reach for Lilly’s later‑life‑cycle products, compounding the pressure on the company’s earnings.
Lilly’s dominance in the GLP‑1 obesity market is increasingly vulnerable to competitive pressures, both from established rivals and new entrants. Novo Nordisk’s Wegovy pill, already launched in the United States, offers a once‑daily oral formulation that has been rapidly adopted by patients seeking convenience, creating a direct substitute that could erode Lilly’s market share. In addition, the market is now subject to a wave of generic and “compounded” versions, exemplified by Hims & Hers’ low‑price oral copy, which threaten to dilute the perceived value of Lilly’s branded products. The company’s own recent data on Retatrutide also highlights higher discontinuation rates in lower‑BMI patients, raising concerns about long‑term adherence and safety that could dampen adoption.
While Lilly’s existing drugs enjoy robust patent protection until the late 2030s, the company is not immune to the broader industry’s patent‑cliff reality. Products such as Verzenio have already plateaued, and late‑life‑cycle medicines like Trulicity and Talsa are expected to be flat or decline, underscoring the cyclical nature of blockbuster revenue. Additionally, the company’s reliance on a few high‑margin assets makes it vulnerable to unexpected regulatory changes or safety concerns that could accelerate patent expiry or force product withdrawals. The potential influx of biosimilar and generic competition in China and other markets could further compress margins, especially for drugs that have yet to secure robust global reimbursement frameworks.
The breadth of Lilly’s pipeline, while a source of upside, also introduces significant regulatory and execution risk. Orforglipron, Lilly’s first oral weight‑loss drug, is still pending FDA approval, and its commercial launch timing remains uncertain, which could delay the expected volume expansion. Retatrutide’s Phase III data, although promising, revealed discontinuation rates tied to perceived excessive weight loss, a red flag that could impede regulatory acceptance or post‑market adoption. Moreover, the company’s aggressive acquisition strategy—spending billions on assets such as Scribe Therapeutics, Orna Therapeutics, and Innovent Biologics—may dilute management focus and increase integration complexity, potentially hampering the execution of its core pipeline priorities.
Finally, macro‑economic and policy uncertainties loom over Lilly’s growth prospects. Rising inflation and higher interest rates could suppress consumer discretionary spending, directly impacting the direct‑to‑consumer model that Lilly is heavily investing in. Unpredictable policy shifts, especially at the state level regarding Medicaid coverage and reimbursement rates, could alter the payer mix in unforeseen ways. The broader pharmaceutical environment is also experiencing heightened scrutiny over drug pricing and value‑based reimbursement, which may result in tighter pricing controls or accelerated reimbursement denial for newer therapies. Together, these factors could erode both volume and margin, making Lilly’s 2026 guidance an optimistic target amid a highly uncertain landscape.